RTTNews BiotechCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-09 20:56:40时区推断·⟳ 抓取 07-11 21:19:54回填·⚡ 决策 07-13 01:37:00·107.0 天前
Virax 与复星诊断签署东南亚多国 ImmuneSelect 商业供应协议，VRAX 盘前已暴涨
协议为商业供应框架且未披露订单金额、采购量、毛利或最低采购承诺，无法量化为确定业绩增量。
📄 原文RTTNews Biotech↗ 原文
Virax Signs Multi-Country Commercial Supply Agreement With Fosun Diagnostics; Stock Skyrockets
Virax Biolabs Group Limited (VRAX) announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered…
不做 Virax Biolabs（VRAX.US）
未披露金额的框架供应协议已触发约 204% 盘前暴涨，且信号抓取滞后约两天，基本面增量不可量化，追高没有可回测正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-09 · 扩散 medium · price-in 风险 high ↗
关键理由
- 协议为商业供应框架且未披露订单金额、采购量、毛利或最低采购承诺，无法量化为确定业绩增量。
- 正文已显示 VRAX.US 在消息后盘前从前收 3.18 美元附近涨至 9.70 美元、涨幅约 204%，短线反应已极端充分。
- 公司近期刚完成 1-for-25 反向拆股，叠加微盘股事件驱动暴涨，追高的回撤和流动性风险大于可验证基本面 edge。
主要风险
- 若后续披露实质性大额采购订单或最低采购义务，事件的重要性可能需要重新评估。
- 未查到可量化的订单金额和收入贡献，不能把区域分销框架等同于确定收入爆发。
原文全文
展开原文 · 2,229 字
Virax Biolabs Group Limited (VRAX) announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product line.
Agreement Scope
The deal covers six Southeast Asian markets— Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia— and establishes a framework for immediate product supply under purchase orders. This structure supports near-term revenue opportunities and positions Virax for regional commercial expansion.
Product Details
ImmuneSelect is Virax's commercially available research-use-only immune profiling product line. It is distinct from ViraxImmune, the company's diagnostic platform currently in clinical and regulatory development.
Strategic Importance
Virax stated that the agreement represents a significant milestone, providing access to multiple Southeast Asian markets through Fosun Diagnostics' established infrastructure and customer network. The framework also supports phased expansion into additional products, higher-volume supply arrangements, and potential OEM or private-label opportunities.
Partner Background
Fosun Diagnostics is part of Fosun Medtech, a division of Fosun Pharma, which reported 2025 revenue of RMB41.662 billion (approximately US$5.8 billion). Fosun Pharma operates globally across pharmaceuticals, medical technologies, diagnostics, and healthcare services.
The company recently implemented a 1-for-25 reverse stock split on June 22, 2026.
VRAX closed Wednesday's trading at $3.18, up 4.61%. In pre-market trading the stock is at $9.70, up 204.00%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 03, 2026 16:09 ET A busy week for economic data saw the release of several reports on the labor market and the manufacturing sector. In the U.S., the jobs report for June was in focus and results of the latest ISM purchasing managers’ survey threw light on the health of the factory sector. In Europe, results of the PMI surveys gained attention while the unemployment figures from Germany were also in news. Similarly in Asia, survey data on the Chinese manufacturing sector was the highlight.
Agreement Scope
The deal covers six Southeast Asian markets— Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia— and establishes a framework for immediate product supply under purchase orders. This structure supports near-term revenue opportunities and positions Virax for regional commercial expansion.
Product Details
ImmuneSelect is Virax's commercially available research-use-only immune profiling product line. It is distinct from ViraxImmune, the company's diagnostic platform currently in clinical and regulatory development.
Strategic Importance
Virax stated that the agreement represents a significant milestone, providing access to multiple Southeast Asian markets through Fosun Diagnostics' established infrastructure and customer network. The framework also supports phased expansion into additional products, higher-volume supply arrangements, and potential OEM or private-label opportunities.
Partner Background
Fosun Diagnostics is part of Fosun Medtech, a division of Fosun Pharma, which reported 2025 revenue of RMB41.662 billion (approximately US$5.8 billion). Fosun Pharma operates globally across pharmaceuticals, medical technologies, diagnostics, and healthcare services.
The company recently implemented a 1-for-25 reverse stock split on June 22, 2026.
VRAX closed Wednesday's trading at $3.18, up 4.61%. In pre-market trading the stock is at $9.70, up 204.00%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 03, 2026 16:09 ET A busy week for economic data saw the release of several reports on the labor market and the manufacturing sector. In the U.S., the jobs report for June was in focus and results of the latest ISM purchasing managers’ survey threw light on the health of the factory sector. In Europe, results of the PMI surveys gained attention while the unemployment figures from Germany were also in news. Similarly in Asia, survey data on the Chinese manufacturing sector was the highlight.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。